A Phase 2 interventional study of Inclisiran and Evolocumab in Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis and Type2 Diabetes, sponsored by Novartis Pharmaceuticals. Completed at 52 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-24.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.
Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 2, and was the 2nd registered.
1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.
Browse Atherosclerosis studies →3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 30–50
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 382 is above the median of 100 across 880 interventional studies indexed under Atherosclerosis.
Median enrollment 401 across the 16 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Atherosclerosis by Novartis: 4 open now, 10 under way, 3 of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 27 studies in Atherosclerosis by Novartis, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 2, and was the 7th registered.
Novartis’s Atherosclerosis studies by the year they started, since 2006.
4 of the studies testing inclisiran in Atherosclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing inclisiran in Atherosclerosis, from their registry updates:
Among Novartis’s 27 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical study was designed to assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C).
MDCO-PCS-16-01 (ORION-3) was a Phase II, open-label, multicenter, non-randomized, active comparator long term extension study. Total study duration was 4 years from first participant enrolled to the last subject completed. The study consisted of three study periods:
Screening Period: Participants completing study MDCO-PCS-15-01 (ORION-1) were screened for all inclusion and exclusion criteria of study ORION-3.
Treatment Period: Participants fulfilling all eligibility criteria of ORION-3 were enrolled. Participants who received inclisiran in ORION-1 received inclisiran sodium throughout this study up to 4 years (Group 1; Inclisiran-only arm), and participants who received placebo in ORION-1 received evolocumab as open-label comparator up to Day 336, and then transitioned to inclisiran on Day 360 and every 180 days thereafter for up to 4 years (Group 2; Switching arm).
Safety follow up: Participants were followed up for safety during 4 weeks after the last dose of study treatment. Including the Screening Period, the total study duration for a participant was up to 4 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Females who are pregnant or nursing, or who are of and unwilling to use at least two methods of (for example, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion are
Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.
Drug: Inclisiran
Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.
Drug: Inclisiran · Drug: Evolocumab
Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Also known as: ALN-PCSSC
Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
Also known as: REPATHA
Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm)
Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study to Day 210 in ORION-3. A negative percentage score represents a reduction in LDL-C. Change is relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Day 210 (ORION-3) (up to 570 days total)
Percentage Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)
Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)
Absolute Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)
Absolute Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)
Percentage Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)
Percent Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Absolute Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)
Absolute Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Percentage Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)
Percent Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Absolute Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)
Absolute Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Percentage Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)
Percent Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Absolute Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)
Absolute Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Percentage Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)
Percent Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Absolute Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)
Absolute Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Number of Participants With ≥50% LDL-C Reduction From Baseline of the ORION-1 Study (Inclisiran Arm)
Number of Participants with ≥50% LDL-C (beta-quantification) Reduction from baseline of the ORION-1 Study overtime in ORION-3. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
Time frame: Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)
Individual responsiveness to inclisiran is defined as the number of Participants Reaching on Treatment LDL-C Levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL at any time point.
Time frame: From the start of treatment in ORION-3 to 90 days after end of treatment, assessed up to maximum duration of 4 years
Participants were recruited from 51 sites in 5 countries.
| Milestone | Inclisiran-only | Switching |
|---|---|---|
| Started | 290 | 92 |
| Safety analysis set | 284 | 90 |
| Completed | 233 | 80 |
| Not completed | 57 | 12 |
| Withdrew: Withdrawal by subject | 25 | 5 |
| Withdrew: Physician decision | 4 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Death | 7 | 1 |
| Withdrew: Adverse event | 9 | 1 |
| Withdrew: Inclusion/exclusion | 1 | 0 |
| Withdrew: Other | 8 | 2 |
Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study to Day 210 in ORION-3. A negative percentage score represents a reduction in LDL-C. Change is relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| Percentage Change | Inclisiran-only |
|---|---|
| Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm) | -47.48 (-50.69 to -44.27) |
Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| Percentage Change | Inclisiran-only |
|---|---|
| Day 30 | -49.43 (-52.27 to -46.58) |
| Day 360 | -37.14 (-40.95 to -33.32) |
| Day 720 | -38.43 (-41.75 to -35.11) |
| Day 1080 | -51.07 (-54.75 to -47.39) |
| Day 1440 | -46.74 (-50.71 to -42.78) |
Absolute Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| mg/dL | Inclisiran-only |
|---|---|
| Day 30 | -62.51 (-66.76 to -58.25) |
| Day 360 | -47.96 (-52.56 to -43.35) |
| Day 720 | -49.44 (-54.25 to -44.64) |
| Day 1080 | -63.34 (-68.76 to -57.92) |
| Day 1440 | -60.04 (-65.81 to -54.27) |
Percent Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| Percentage Change | Inclisiran-only |
|---|---|
| Day 30 | -71.80 (-73.17 to -70.44) |
| Day 360 | -63.79 (-65.79 to -61.80) |
| Day 720 | -62.17 (-64.46 to -59.88) |
| Day 1440 | -69.54 (-71.19 to -67.89) |
Absolute Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| ug/L | Inclisiran-only |
|---|---|
| Day 30 | -314.07 (-328.69 to -299.45) |
| Day 360 | -280.88 (-295.71 to -266.06) |
| Day 720 | -275.78 (-291.91 to -259.64) |
| Day 1440 | -314.34 (-331.22 to -297.46) |
Percent Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| Percentage Change | Inclisiran-only |
|---|---|
| Day 30 | -1.71 (-6.42 to 3.00) |
| Day 210 | -3.35 (-9.12 to 2.41) |
| Day 1440 | 0.73 (-8.23 to 9.69) |
Absolute Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| mg/dL | Inclisiran-only |
|---|---|
| Day 30 | -14.61 (-22.15 to -7.08) |
| Day 210 | -11.96 (-23.78 to -0.14) |
| Day 1440 | -14.83 (-25.75 to -3.90) |
Percent Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| Percentage Change | Inclisiran-only |
|---|---|
| Day 30 | -40.43 (-42.57 to -38.29) |
| Day 210 | -36.65 (-39.06 to -34.23) |
| Day 1440 | -33.66 (-37.18 to -30.15) |
Absolute Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| mg/dL | Inclisiran-only |
|---|---|
| Day 30 | -42.63 (-45.22 to -40.04) |
| Day 210 | -38.36 (-41.19 to -35.54) |
| Day 1440 | -36.26 (-40.01 to -32.52) |
Percent Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| Percentage Change | Inclisiran-only |
|---|---|
| Day 30 | -15.88 (-19.48 to -12.28) |
| Day 210 | 9.29 (4.42 to 14.16) |
| Day 1440 | -5.24 (-9.86 to -0.61) |
Absolute Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| nmol/L | Inclisiran-only |
|---|---|
| Day 30 | -8.52 (-12.25 to -4.79) |
| Day 210 | -4.94 (-8.67 to -1.20) |
| Day 1440 | -4.78 (-9.63 to 0.06) |
Number of Participants with ≥50% LDL-C (beta-quantification) Reduction from baseline of the ORION-1 Study overtime in ORION-3. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.
| Participants | Inclisiran-only |
|---|---|
| Day 30 | 161 |
| Day 360 | 99 |
| Day 720 | 97 |
| Day 1440 | 122 |
Individual responsiveness to inclisiran is defined as the number of Participants Reaching on Treatment LDL-C Levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL at any time point.
| Participants | Inclisiran-only |
|---|---|
| LDL-C level <25 mg/dL | 82 |
| LDL-C level <50 mg/dL | 175 |
| LDL-C level <70 mg/dL | 225 |
| LDL-C level <100 mg/dL | 265 |
Collected over Adverse events were reported from first dose of study treatment in ORION-3 up to end of study visit, assessed up to maximum duration of 4 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclisiran Only Arm | 7/284 (2.5%) | 104/284 (36.6%) | 271/284 (95.4%) |
| Switching Arm up to Day 360 Visit | 0/90 (0%) | 16/90 (17.8%) | 78/90 (86.7%) |
| Switching Arm After Day 360 Visit | 1/87 (1.1%) | 30/87 (34.5%) | 77/87 (88.5%) |
| Event | Inclisiran Only Arm | Switching Arm up to Day 360 Visit | Switching Arm After Day 360 Visit |
|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 4/284 | 1/90 | 3/87 |
| Angina pectorisCardiac disorders | 7/284 | 0/90 | 1/87 |
| Acute myocardial infarctionCardiac disorders | 4/284 | 1/90 | 2/87 |
| Transient ischaemic attackNervous system disorders | 4/284 | 0/90 | 2/87 |
| Hypertensive urgencyVascular disorders | 0/284 | 0/90 | 2/87 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 0/284 | 2/90 | 0/87 |
| COVID-19Infections and infestations | 6/284 | 0/90 | 1/87 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 6/284 | 0/90 | 0/87 |
| Angina unstableCardiac disorders | 5/284 | 1/90 | 0/87 |
| Atrial fibrillationCardiac disorders | 4/284 | 1/90 | 1/87 |
| Event | Inclisiran Only Arm | Switching Arm up to Day 360 Visit | Switching Arm After Day 360 Visit |
|---|---|---|---|
| HypertensionVascular disorders | 42/284 | 2/90 | 17/87 |
| NasopharyngitisInfections and infestations | 55/284 | 6/90 | 13/87 |
| Back painMusculoskeletal and connective tissue disorders | 28/284 | 1/90 | 13/87 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 40/284 | 10/90 | 10/87 |
| Urinary tract infectionInfections and infestations | 37/284 | 6/90 | 7/87 |
| InfluenzaInfections and infestations | 36/284 | 6/90 | 10/87 |
| FatigueGeneral disorders | 23/284 | 3/90 | 10/87 |
| Diabetes mellitusMetabolism and nutrition disorders | 32/284 | 0/90 | 6/87 |
| DiarrhoeaGastrointestinal disorders | 17/284 | 3/90 | 9/87 |
| HeadacheNervous system disorders | 21/284 | 8/90 | 7/87 |
All enrolled participants
| Age, Continuous(Year) | Inclisiran-only | Switching | Total |
|---|---|---|---|
| Mean | 63.3 ± 11.14 | 61.9 ± 10.56 | 63.0 ± 11.01 |
| Sex: Female, Male(Participants) | Inclisiran-only | Switching | Total |
|---|---|---|---|
| Female | 102 | 37 | 139 |
| Male | 188 | 55 | 243 |
| Ethnicity (NIH/OMB)(Participants) | Inclisiran-only | Switching | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 7 | 22 |
| Not Hispanic or Latino | 275 | 85 | 360 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2017 to primary completion in Dec 2021, 55 months.
Results were first posted in Mar 2023, 1 year 3 months after primary completion.
Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 55 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran